Overall, the integrated genetic, transcriptomic, and metabolic evidence links defined molecular perturbations to plausible treatment avenues, providing a mechanistic bridge between pathophysiology and therapeutic development in both GBA1-related and sporadic Parkinson’s disease. The gene discussed is GBA1; the disease is Parkinson disease.